BioSpace News Archive

Policy

COVID-19 Update: Contradictory J&J Data and a 4th Shot Likely for 50 Plus

COVID-19 vaccines are the most-studied vaccines in history. This is partly why some data can appear so contradictory. For those and more COVID-19 stories, continue reading.

March 28, 2022
·
5 min read
·
Mark Terry
Drug Development

Global Roundup: RDIF Touts Efficacy of Sputnik V in HIV Patients

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

March 28, 2022
·
4 min read
·
Alex Keown
Business

Bayer Stakeholder Temask May Call for CEO Baumann’s Ouster

Per Bloomberg: Singapore-based Temask Holdings is calling for the installation of a new chief executive officer at Bayer.

March 28, 2022
·
2 min read
·
Alex Keown
Drug Development

Examining the Debilitating Effects of Post-COVID Parosmia

Typically occurring after sufferers regain their total smell loss from anosmia, parosmia is an olfactory disorder that causes smell distortions.

March 28, 2022
·
7 min read
·
Abbey Glasure
Business

Civica is Rallying Leaders to Make Affordable Insulin by 2024

Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.

March 28, 2022
·
8 min read
·
Heather McKenzie
Drug Development

Long COVID: New Insights Could Provide Treatment Options

Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.

March 28, 2022
·
3 min read
·
Hayley Shasteen
Drug Development

AACR Preview: AstraZeneca to Showcase “Oncology Revolution”

AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.

March 28, 2022
·
3 min read
·
Alex Keown
Business

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

GH Research PLC today reported financial results for the full year ended December 31, 2021 and gave updates on its business.

March 28, 2022
·
8 min read
Drug Development

Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting

Nimbus Therapeutics today announced that it will present preclinical data from its Casitas B-lineage lymphoma b (Cbl-b) program at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.

March 28, 2022
·
1 min read
Business

BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended December 31, 2021 and provided a corporate update.

March 28, 2022
·
12 min read